

Research Paper**Azamacrocyclic Complexes: Synthesis and Xanthine Oxidase and Antioxidant Activity****ABSTRACT**

Gout is caused by high uric acid (hyperuricemia) in the blood that leads to excess uric acid crystallizing in the joints causing swelling and pain. This is either caused by the over production of uric acid or under excretion by the kidneys. Uric acid is produced from the breakdown of the purine which is released when cells die or introduced from the food we eat. Under normal conditions, uric acid is supposedly produced in enough quantities so as to be efficiently removed by fully-functioning kidneys. There are cases however when specific enzyme defects cause excessive production of uric acid. The enzyme that helps in breakdown of purine to uric acid is xanthine oxidase (XO). Since XO makes the conversion of purine into uric acid happen, preventing its activity results to slow down of uric acid production. Such is the role of xanthine oxidase inhibitors (XOI). Macrocylic metal complexes containing phenylene bridges have been synthesized and subjected to biological activities. Among the four synthesized complexes (3a-3d), 3d exhibited 83.2% of XO inhibition and also showed potent antioxidant activity. The same was also evident from structure activity relationship with atomic contact energy values of -285.78 compared to allopurinol with -200.02. From the present study, we infer that, azamacrocyclic metal complexes could lead to the development of newer therapeutics for gout and other inflammatory diseases which are caused by oxidative stress.

Keywords: Antioxidant activity, azamacrocyclic complexes, Molecular docking, xanthine oxidase.

28

29

30

31 1. INTRODUCTION

32 Xanthine oxidase (XO), a molybdoflavo protein, is a key enzyme in purine metabolism that has
33 been isolated from a wide range of organisms, including bacteria and humans [1, 2]. The XO
34 catalyzes the hydroxylation of hypoxanthine and xanthine to yield uric acid and hydrogen
35 peroxides. The enzyme is responsible for the medical condition known as gout which is caused
36 by the deposition of uric acid in the joints leading to painful inflammation [3]. It has attracted
37 lots of attention because of its potential role in tissue and vascular injuries, as well as in
38 inflammatory diseases and chronic heart failure [4, 5]. The production of reactive oxygen species
39 (ROS) by XO and its damaging consequences has prompted investigations into the ability of
40 some compounds to control and/or inhibit the enzyme activity or to scavenge the free radicals
41 produced [6, 7]. Allopurinol (1, 5-dihydro-4Hpyrazolo [3, 4-d] pyrimidin-4-one), a purine
42 analogue was the first XO inhibitor approved by the FDA in 1966 and has been the cornerstone
43 of the clinical management of gout and conditions associated with hyperuricemia for several
44 decades [4]. However due to lack of free radical scavenging activity against superoxide anions
45 produced, use of allopurinol is associated with some side effects that include allergy,
46 hypersensitivity reactions, gastrointestinal upset, skin rashes and acute interstitial nephritis [5].
47 Therefore there is a need for the development of novel compounds with better safety profiles that
48 could be used to relieve associated side effects.

Alterations of XO activity by various metals have also been probed with mixed results of either stimulation or inhibition, depending on the metal [8]. As mentioned above, because of its ubiquity and its ability to bind to proteins, copper would be one of the metals to probe in priority. However, although partial inhibition of XO activity by Cu^{2+} has been reported [9] there is no thorough investigation on the effect of the metal on the enzyme activity and structure, nor on the potential attachment sites for the metal.

Damage to cells caused by free radicals is believed to play a central role in the aging process and in disease progression. Antioxidants are our first line of defense against free radical damage, and are critical for maintaining optimum health and wellbeing. Some of the more well-known antioxidants include ascorbic acid (Vitamin C), alpha-tocopherol (Vitamin E), beta-carotene and enzymes such as catalase, superoxide dismutase (SOD) and glutathione peroxidase. The need for antioxidants becomes even more critical with increased exposure to free radicals [10].

Transition metal complexes have notably shown important antioxidant properties, viz SOD mimetic activity [11]. The macrocyclic nature of the ligand seems important for the SOD mimetic activity of the corresponding complexes as well as for their stability in the presence of proteins, even if the metal ion does not lie inside the cavity [12]. Copper (II) complexes can enclose a SOD mimetic activity hindering increased levels of reactive oxygen species [13]. Several macrocyclic copper complexes have been reported to scavenge the superoxide anion [14-17].

Among the non-platinum complexes for metal based chemotherapy, copper and zinc complexes have been much explored due to the fact that both copper and zinc are bioessential elements responsible for numerous bioactivities in living organism [18]. A number of nitrogen donor

macrocyclic derivatives have long been used in analytical, industrial and medical applications [19-21].

Considering the importance of macrocyclic metal complex as XOI and antioxidant, the objective of the present study was to synthesize aza macrocyclic ligand and its metal complexes by using simple condensation method. The synthesized compounds were subjected to biological study and among these complexes, 3d exhibited potent XOI and antioxidant property.

2. EXPERIMENTAL SECTION

2.1 Materials and methods

All the reagents used in the preparation of macrocyclic Ligands and their metal complexes were of reagent grade(Merck).The solvents used for the synthesis of macrocyclic ligands and metal complexes were distilled before use. All other chemicals were of AR grade and used without further purification. The elemental analysis of the compounds was performed on a Perkin Elmer 2400 Elemental Analyser. The FT-IR spectra were recorded using KBr discs on FT-IR Jasco 4100 infrared spectrophotometer. The ^1H NMR spectra were recorded using Bruker DRX 400 spectrometer at 400 MHz with TMS as the internal standard. The magnetic moments were measured out using gouy balance. Purity of the compound checked by TLC.

2.2. Chemistry

Preparation of the Macrocyclic ligand and its metal complexes (3a-d)

The macrocyclic ligand and its metal complex **3a-d** were synthesized by the template condensation of 2, 3, 5, 6-tetra methyl, 1, 4-diaminobenzene in MeOH, a solution of 36% formaldehyde in MeOH was added. After stirring for 10 min a solution of 1, 4-diaminobutane in MeOH was added. Finally a solution of metallic salt and 2, 4-pentanedione in MeOH was added and the resulting mixture was refluxed for ca. 7 hrs. The brown solid product was filtered off,

washed with MeOH and dried over fused CaCl_2 in desiccators. The product was recrystallized from hot MeOH.

2.2.1 Synthesis of copper (II) complex (3a)

The macrocyclic ligand and its metal copper complex were synthesized by the template condensation of 2, 3, 5, 6-tetra methyl, 1, 4-diaminobenzene (1g, 0.0061 mol) in MeOH (20 cm^3), a solution of 36% formaldehyde (0.0061mol, 0.7 cm^3) in MeOH (20 cm^3) was added. After stirring for 10 min a solution of 1, 4-diaminobutane (0.0061mol, 2.447 cm^3) in MeOH (20 cm^3) was added. Finally a solution of $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (0.0061 mol, 1.0g) and 2, 4-pentanedione (0.0061 mol, 1.2428 cm^3) in MeOH (40 cm^3) was added and the resulting mixture was refluxed for ca. 7 hrs. The brown solid product was filtered off, washed with MeOH and finally washed with water. The solid obtained was dried over fused CaCl_2 in desiccators.

Yield: 70%. Brown solid; IR (Nujol): 3271 (N-H), 1605 cm^{-1} (C=N), 1182 (C-N), 456 (Cu-N), 332 cm^{-1} (Cu-SO₄); ^1H NMR (CDCl_3): 0.9 (s, 12H, 4CH₃), 1.3 (m, 8H, 4CH₂-N=C), 1.3 (t, 8H, 4CH₂-N=C=), 1.41 (m, 8H, 4CH₂), 2.35 (s, 12H, 4Ar-CH₃), 2.55 (t, 8H, 4CH₂), 3.31 (s, 4H, 2CH₂), 4.61 (s, 8H, 4CH₂); Anal. Calcd. for $\text{C}_{40}\text{H}_{72}\text{N}_{10}\text{Cu}_2\text{S}_2\text{O}_8$ (1011.1): C, 47.473 ; H,7.121 ; N, 13.85; Cu, 12.57; S,6.329; O, 12.66%. Found: C, 47. 3; H, 7.15; N, 13.67; Cu, 12.48; S, 6.4; O, 12.4%.

2.2.2. Synthesis of nickel (II) complex (3b)

The macrocyclic nickel (II) complex was prepared by a method similar to that for copper complex except that $\text{NiCl}_2 \cdot 6\text{H}_2\text{O}$ was used instead of $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$.

Yield: 85%. Brown solid; IR (Nujol): 3260 (N-H), 1601 cm^{-1} (C=N), 1172 (C-N), 453 (Ni-N), 320 cm^{-1} (Ni-Cl); ^1H NMR (CDCl_3): 0.9 (s, 12H, 4CH₃), 1.3 (m, 8H, 4CH₂-N=C), 1.3 (t, 8H,

117 4CH₂-N=C=), 1.41 (m, 8H, 4CH₂), 2.35 (s, 12H, 4Ar-CH₃), 2.55 (t, 8H, 4CH₂), 3.31 (s, 4H,
118 2CH₂), 4.61 (s, 8H, 4CH₂); Anal. Calcd. for C₄₀H₇₂N₁₀Ni₂Cl₄ (951.2): C, 50.46 ; H,7.569 ; N,
119 14.718; Ni, 12.342; Cl, 14.9 Found: C, 50.34 ; H,7.62 ; N, 14.48; Ni, 12.232; Cl, 14.88%.

120 2.2.3 Synthesis of zinc (II) complex (3c)

121 The macrocyclic zinc complex was prepared by a method similar to that for copper complex
122 except that ZnCl₂ was used instead of CuSO₄.5H₂O.

123 Yield: 90%. Pale yellow solid; IR (Nujol): 3250 (N-H), 1615 cm⁻¹ (C=N), 1175 (C-N), 446 (Zn-
124 N), 325 cm⁻¹ (Zn-Cl); ¹H NMR (CDCl₃): 0.9 (s, 12H, 4CH₃), 1.3 (m, 8H, 4CH₂-N=C), 1.3 (t, 8H,
125 4CH₂-N=C=), 1.41 (m, 8H, 4CH₂), 2.35 (s, 12H, 4Ar-CH₃), 2.55 (t, 8H, 4CH₂), 3.31 (s, 4H,
126 2CH₂), 4.61 (s, 8H, 4CH₂); Anal. Calcd. for C₄₀H₇₂N₁₀Zn₂Cl₄ (964.56): C, 49.76 ; H,7.465 ; N,
127 14.51; Zn, 13.56; Cl, 14.7 Found: C, 49.45 ; H, 7.44 ; N, 14.73; Zn, 13.48; Cl, 14.59%

128 2.2.4. Synthesis of Silver (I) complex (3d)

129 The macrocyclic silver complex were prepared by a method similar to that for copper complex
130 except that Silver nitrate was used instead of CuSO₄.5H₂O.

131 Yield: 65%. Dark brown solid; IR (Nujol): 3269 (N-H), 1598 cm⁻¹ (C=N), 1201 (C-N), 461
132 (Ag-N), 343 cm⁻¹(Ag-NO₃); ¹H NMR (CDCl₃): 0.9(s, 12H, 4CH₃), 1.3 (m, 8H, 4CH₂-N=C), 1.3
133 (t, 8H, 4CH₂-N=C=), 1.41 (m, 8H, 4CH₂), 2.35 (s, 12H, 4Ar-CH₃), 2.55 (t, 8H, 4CH₂), 3.31 (s,
134 4H, 2CH₂), 4.61 (s, 8H, 4CH₂); Anal. Calcd. for C₄₀H₇₂N₁₂Ag₂O₆ (1031.72): C, 46.52 ; H,
135 6.9786 ; N, 16.28; Ag, 20.908; O, 9.3048%. Found: C, 46.48 ; H,7.12 ; N, 16.12; Ag, 20.89; O,
136 9.209%

137 3. BIOLOGY

138 3.1 XANTHINE OXIDASE INHIBITION STUDIES:

The XO inhibitory activity was monitored spectrophotometrically (UV-1800, Japan) following the absorbance of uric acid at 292 nm [22, 23]. Briefly, rat liver was excised, perfused and homogenized in 0.01 M Tris-HCl pH (8.0) containing 1 mM EDTA. The homogenate was centrifuged and the supernatant was used as a source of enzyme. It was stored at -80° C until use and the protein content was determined by the Lowry's method [24], using bovine serum albumin (BSA) as standard.

The enzyme assay mixture consisted of 20 mM potassium phosphate buffer (pH 7.4) containing 0.3 mM EDTA and the enzyme source in a total volume of 2 mL. In dose dependent inhibition studies, the reaction was initiated by the addition of xanthine (50 µM) as the substrate to the above assay mixture and the test compounds. The absorption rate at a wavelength of 292 nm indicates the formation of uric acid at 10 min intervals at ambient temperature. Duplicate assays were repeated thrice. Allopurinol was used as positive control and DMSO was used as blank. The inhibitory activity of each test compound against XO was indicated by their IC₅₀ values. The percentage inhibition of XO activity was calculated using the following formula.

$$\text{Xanthine oxidase Inhibition (\%)} = \frac{\text{Abs control} - \text{Abs sample}}{\text{Abs control}} \times 100$$

Abs control = Absorbance of the control reaction (containing all reagents except the test compound). Abs sample = Absorbance of the test compound.

3.2 Antioxidant activity

Chemicals

Butylated hydroxy anisole(BHA), 1,1-diphenyl-2-picrylhydrazyl (DPPH), thiobarbituric acid (TBA), ethylenediaminetetra acetic acid (EDTA), trichloroacetic acid (TCA), deoxyribose, and

ascorbic acid were obtained from M/s (Sisco Research laboratories, Mumbai, India). All reagents were of analytical grade.

Biology

3.2.1 DPPH Radical scavenging assay

DPPH radical-scavenging assay was done according to Yamaguchi, Takamura, Matoba, and Treao (1998) [25]. Briefly, 1 mL of DPPH solution (0.1 mM, in 95% ethanol (v/v)) was incubated with different concentrations of the compounds. The reaction mixture was shaken and incubated for 20 min at room temperature and the absorbance was read at 517 nm against a blank. The antioxidant BHA was used as a positive control in all the assays. The radical scavenging activity was measured as a decrease in the absorbance of DPPH and calculated using the following equation:

$$\text{Scavenging effect (\%)} = [(A_{\text{control}} - A_{\text{sample}}) / A_{\text{control}}] \times 100$$

Where A= absorbance.

3.2.2. Lipid per oxidation assay

Lipid peroxidation (LPO) inhibitory activity was measured according to Kulkarni, Aradhya, and Divakar (2004) [26]. Egg lecithin (3 mg/mL in phosphate buffer, pH 7.4) was sonicated (Hielscher GmbH UP 50H ultra-challprocessor sonicator) for 30 min to obtain small membrane liposome vesicles. Different concentrations of the compounds were added to 0.5 mL of liposome mixture. Lipid peroxidation was induced by adding 10µL of 400 mM FeCl₃ and 10 µL of 200

183 mM L- ascorbic acid. After 60 min of reaction at 37 °C, the reaction was stopped by the addition
184 of 1 mL of 0.25 N HCl containing 15% TCA and 0.375% TBA and incubation in a boiling water
185 bath for 15 min. After centrifugation at 10,000 rpm, absorbance of the supernatant was measured
186 at 532 nm. The scavenging effect was calculated using the equation as described for DPPH.

187 3.2.3. Reducing power assay

188 The reducing power was measured by incubating the reaction mixture (1mL) containing the
189 samples in the phosphate buffer (0.2 M, pH 6.6) with potassium ferricyanide (1 g/100 mL water)
190 at 50 °C for 20 min. The reaction was terminated by adding TCA (10g/100mL water), the
191 mixture was centrifuged at 3000 rpm for 10 min and the supernatant was mixed with ferric
192 chloride (0.1 g/100 mL of water); the absorbance was measured at 700 nm [27]. Increased
193 absorbance of the reaction mixture indicated increased reducing power.

194 3.2.4. Hydroxyl radical-scavenging activity

195 The reaction mixture, containing compound(at different concentration) was incubated with
196 deoxyribose (15 mM), H₂O₂ (10 mM), FeCl₃ (500 μM), EDTA (1 mM) and ascorbic acid (1mM)
197 in potassium phosphate buffer (100 mM) pH 7.4 for 60 min at 37 °C. The reaction was
198 terminated by adding 1 ml TBA (1% w/v) and then heating tubes in a boiling water bath for 15
199 min. The contents were cooled and the absorbance of the mixture was measured at 535 nm
200 against the reagent blank.

201 3.2.5. Metal ion chelating assay

202 The Fe²⁺ chelating ability of the extract was measured by the ferrous iron-ferrozine complex at
203 562nm (Decker & Welch, 1990) [28]. The reaction mixture containing FeCl₂ (2 mM/L) and

ferrozine (5 mM/L) along with extracts was adjusted to a total volume of 0.8 mL with methanol, mixed and incubated for 10 min at room temperature. The absorbance of the mixture was read at 562nm against a blank. EDTA was used as positive control. The ability of the extract to chelate ferrous ion was calculated using the equation described for DPPH.

3.3. Statistical analysis

All experiments were carried out in triplicates and repeated in three independent sets of experiments. Data are shown as means± standard deviation (SD). The SPSS10.0.5 version for windows (SPSS software Inc., USA) computer programme was used for statistical analysis. The significance of the study was assessed by one way ANOVA, followed by hoc comparison test. Correlations between quantitative properties were evaluated by calculating the Duncan and Dunnett's co-efficient. Statistical significance value was set at $p < 0.05$.

4. Molecular docking

The human milk xanthine oxidase (HMXO) (EC: 1.17.3.2) is mainly associated with gout disorder and subsequently for other diseases. The crystal structure of HMXO was studied with PDB: 2CKJ was built using CPH Models server 3.0. Energy computations were performed on the molecule using GROMOS 96 implementation of Swiss-PDB Viewer. Electrostatic point charges on the molecules were calculated. The structures of XO of the current study were constructed using a public domain web server Dundee PRODRG Server [29] which optimizes the conformation of the side chains and minimizes the energy. The ligand was saved in PDB format. The minimum energy conformers of ligands were interactively docked into close proximity with the enzyme active site pocket. The possibility of binding, precise location of binding sites and mode of ligand binding was carried out using an automated docking software,

Molegro Virtual Docker 2008, version 3.2.1 (Molegro ApS, Aarhus, Denmark, <http://molegro.com>), that is based on guided differential evolution and a force field based screening function [30]. Possible binding conformation and orientations were analyzed by clustering methods, embedded in Molegro Molecular Viewer 2008, version 1.2.0. Docking studies were carried out using the HMXO model. The enzyme was visualized using sequence option, A and B chain, salicylic acid, water, co-factors except molybdenum were deleted. The C chain as well as molybdenum co-factor was retained and subjected to docking studies. Molecular structures of the imported ligands were manually checked and corrected before docking. The initial geometry and topologies of the protein and ligand were imported to Molegro Virtual Docker. The binding site was computed within spacing such that the binding site was well sampled with a grid resolution of 0.3 Å. The ligand was docked into this grid using the MolDock Optimizer algorithm and its interactions monitored using detailed energy estimates. A maximum population of 100 and maximum interactions of 10,000 were used for each run and the 5 best poses were retained. The software Molegro Molecular Viewer 2008, version 1.2.0 (<http://molegro.com>) was utilized to identify hydrogen bonds and hydrophobic interactions between residues at the active site and the ligand.

5. Results and discussion

5.1. Chemistry

Aza macrocyclic metal complexes were prepared by reacting 1 equivalent of tetra methyl phenylene diamine with 4 equivalent of formaldehyde, 4 equivalents of 1, 4-diaminobutane and 2 equivalent of 2, 4-pentanedione in the presence of metallic salt. Aza macrocyclic products obtained are air stable but during the preparation of complex the reaction was affected by the

249 molar ratio of the reactant. All the complexes were synthesized by similar method except
250 metallic salt. The elemental analysis data of the complexes are in good agreement with
251 theoretical values. The molar conductance of all the complexes in DMSO show that they are
252 non-electrolytes.

253 The infrared spectra gave some important information regarding to the skeleton of the
254 complexes. The important IR spectral bands of all the four complexes (3a-d) exhibit an intense
255 band around 3270 cm^{-1} region which may be assigned to stretching ν (N-H) of the coordinated
256 secondary amino group. All the complexes show bands in the 1600 cm^{-1} region, attributed to
257 coordinated ν (C=N). A band in the 1180 cm^{-1} region is assigned to the ν (C-N) vibration in all
258 the complexes, and bands in the region $2800\sim 2850\text{ cm}^{-1}$ and $1445\sim 1455\text{ cm}^{-1}$ region, to ν (C-H)
259 and ν (C-H) respectively. On the other hand, the complexes have no bands assignable to carbonyl
260 group stretching modes, which indicates that the carbonyl groups are not involved in
261 coordination bond. The coordination of nitrogen to the metal atom is supported by the
262 appearance of a new band in the region $430\sim 478\text{ cm}^{-1}$ assignable to (M-N) vibration. It confirms
263 the involvement of nitrogen in coordination. The M-X vibrations were identified through the
264 bands appeared in the region $320\sim 350\text{ cm}^{-1}$ for all the complexes.

265 The magnetic moments of Ni (II) complex are a little higher than the calculated values, possibly
266 due to ferromagnetic interactions, in accordance with other octahedral. The magnetic moment
267 value of this complex was found 3.16 BM which indicates the octahedral environment around
268 the metal ion. The magnetic moment of Cu (II) complex was found 1.83 BM which confirmed
269 the distorted octahedral geometry. The Zn (II) complex is found to be diamagnetic. On the basis
270 of elemental analyses, IR, and magnetic moment values the probable structure of complexes
271 have been given in Fig. 1.




Figure: 1

5.2. Biology

The aza macrocyclic complexes were synthesized as depicted in Scheme 1. Complex compounds were screened for the XO inhibition and antioxidant activity. The effect of different doses of metal complexes on XO in rat liver is shown in Table 1. The significant inhibition was shown by complex 3d with silver as central metal ion, followed by complex 3c with zinc, complex 3b with nickel and complex 3a with copper. These compounds showed potent inhibitory activity near to allopurinol. All the four complex compounds showed good inhibitory activity (Table 1). Complex 3d with silver as central metal ion is the most potent of all the inhibitory compounds tested, may be this is due to high soluble property of the complex in all solvents including water whereas other complexes are poorly soluble in other organic solvents and soluble in DMSO (3d > 3c > 3b > 3a). Further, the inhibitory activity of the newly synthesized complex compounds (3a-d) against XO was studied using the method of Kadam and Iyer [22] and Litwack *et al* [23]. Rate of formation of uric acid from the oxidation of xanthine in presence of these inhibitors against different sources of XO was studied. The inhibitory activity of synthesized complex compounds was compared with the inhibitory activity shown by the standard inhibitor allopurinol. All the four complex compounds were tested for their ability to block the XO

291 activity for the substrate xanthine. Present study identifies a new class of XO inhibitor. The
292 inhibitory property of synthesized complex compounds was investigated in this work and we
293 found that it effectively inhibited the enzymatic formation of uric acid from xanthine. The
294 known X-ray structure of xanthine oxidoreductase bound molecule shows highly specific
295 binding pocket presenting a long narrow cavity leading towards the Mo (IV) complex.
296 Molybdenum protein site of both XO and xanthine dehydrogenase are structurally equivalent.
297 Further, to understand the binding mode of newly synthesized complex compounds with XO,
298 molecular docking studies of the compounds (3a-d) and the structure of XO (PDB entry code
299 2CKJ) was obtained from protein data bank. The protein was prepared by removing the ligands
300 and substrate, however, active site of amino acids was retained [31]. It is possible that
301 diaminobenzene nucleus bind to active site and pentanedione may bind to the peripheral site of
302 enzyme and transfer electrons to molybdenum center (α_2) electron acceptor from no site of XO.
303 All the complex compounds were tested for their ability to block the XO activity for the substrate
304 xanthine. The present study helps to understand structural activity relationship mode of
305 interaction and extent of inhibition of complex compounds against rat liver (*in vitro*) and human
306 milk XO (*in silico*).

307




Table 1: Comparative inhibitory activities of compounds **1-4** against Rat liver xanthine oxidase in percentage inhibition.

Compounds	Rat liver
3a	15.3 %
3b	24.2 %
3c	61 %
3d	83.2 %
Allopurinol	100 %

The mode of interaction was analyzed by docking using human milk XO (PDB Code - 2CKJ) on selected active site of amino acids of chain C and molybdenum. Complexes were subjected for structure activity relationship and their structure permitted various modes of

interaction with active site of amino acid. Compound **3d** produced relatively better activity against HMXO (83.2% inhibition) which was also supported by docking studies (figure 2 and table 2). The level of XO in the serum is significantly increased in several pathological statuses. Thus inhibition of this enzyme by complex compounds may have properties that are of therapeutic interest.

Figure 2: Docking results of compound 3a, 3b, 3c and 3d with standard allopurinol.





Table 2: Hydrogen bonding between the docked top ranked pose of potent compounds and standard against human milk XO.

Sl. No	Description of the compound	Residues in H bonding	No. of H bond interaction and energy	Atomic contact energy values
1	3a	Gly 45, Gly 262	0	- 221.04
2	3b	Asp 69, Gln 60, Asn 129, Ser 343)	3 (-0.71, -0.13, - 2.37)	- 241.21
3	3c	Lys 57, Asp 59, Ser 305, Leu 306)	5 (1.30, 1.33, 2.25, -2.5, -1.57)	- 265.10
4	3d	Lys 57, Asn 287, Ser 305,	4 (2.57, -0.13, -2.46, - 0.90)	- 285.78
5	Std (allopurinol)	Ala 301, Gly 350	2 (-2.8, -2,2)	- 200.02

In order to evaluate the radical–scavenging ability of the complex compounds 3a-d DPPH radical scavenging assay, lipid peroxidation assay, reducing power assay, hydroxyl radical-scavenging and metal chelating activities was employed. Compounds 3a-c shown very poor activity for all the above assays. Compound 3d showed to be a moderately potent DPPH radical scavenger that is known to abstract the labile hydrogen atom. It also inhibited the peroxidation of lipids. The antioxidant activity of compound 3d with IC₅₀ value of 15.21 µg/mL, and synthetic antioxidant BHA was 13.81µg/mL (Fig. 3). Proton radical-scavenging action is an important attribute of antioxidants; however, hydrogen donating ability of the antioxidant molecule contributes to its free radical-scavenging nature [32].

355


356 **Figure 3:** DPPH scavenging assay of potent compound 3d



357

358 Initiation of peroxidation sequence in a membrane is due to abstraction of a hydrogen atom from
 359 a double bond in the fatty acid. The antioxidant activities of complex 3d and BHA with the IC_{50}
 360 value of 15.38 µg/mL and 13.72 µg/mL respectively (Fig. 4). The free radical tends to stabilize
 361 by a molecular rearrangement to produce a conjugated diene, which then readily reacts with an
 362 oxygen molecule to give a peroxy radical [33].


363 **Figure 4:** Inhibition of Lipid per oxidation by potent compound 3d



364

It is believed that antioxidant activity and reducing power are related [34]. Reductones inhibit lipid peroxidation by donating a hydrogen atom and thereby terminating the free radical chain reaction [27]. All the compounds showed the concentration dependent activity (Fig. 5).

Figure 5: Reducing power assay of potent compound 3d



Complex 3d and BHA displayed hydroxyl radical scavenging activity with IC_{50} values of 16.37 $\mu\text{g/mL}$, 14.59 $\mu\text{g/mL}$ respectively (Fig. 6). The hydroxyl radical is an extremely reactive free radical formed in biological systems and has been implicated as a highly damaging species in free radical pathology, capable of damaging biomolecules of the living cells [35]. Hydroxyl radical has the capacity to cause DNA strand breakage, which contributes to carcinogenesis, mutagenesis and cytotoxicity. In addition, this radical species is considered as one of the quick initiators of the LPO process, abstracting hydrogen atoms from unsaturated fatty acids. Further, Metal chelating ability was also accessed for complex 3d and EDTA with IC_{50} values of 16.1 $\mu\text{g/mL}$, 13.97 $\mu\text{g/mL}$ respectively (Fig. 7).

Figure 6: Hydroxyl radical scavenging assay of potent compound 3d





Figure 7: Metal ion chelation assay of potent compound



Conclusion

From the results of the present study, it is concluded that, aza macrocyclic metal complexes 3a-d were synthesized and their XO inhibitory and antioxidant activities have been evaluated. Compounds 3d demonstrated potent inhibitory activities against XO and a good antioxidant. Further research in this area is in progress in our laboratory.

391 **Conflict of interest**

392 The authors declare that they have no conflicts of interest with respect to the content of the
393 manuscript.

394 **Acknowledgements**

395 We the authors express our sincere gratitude to the University of Mysore, Mysore and
396 Department of Chemistry, Yuvaraja's college, Mysore for the laboratory facilities provided to us.
397 One of the authors SAK gratefully acknowledged the financial support provided by the Vision
398 Group on Science and Technology, Government of Karnataka, under the scheme CISEE,
399 Department of Information Technology, Biotechnology and Science & Technology. Bangalore.

400 **References**

401

- 402 1. Harrison R. Structure and function of xanthine oxidoreductase: Where are we now? Free
403 Rad Biol Med. 2002; 33: 774-797.
- 404 2. Parks DA, Granger DN. Xanthine oxidase: biochemistry, distribution and physiology.
405 Acta Physiol Scand. 1986; 548: 87-99.
- 406 3. Zhong-Lu You, Da-Hua Shi, Chen Xu, Qiang Zhang, Hai-Liang Zhu. Schiff base
407 transition metal complexes as novel inhibitors of xanthine oxidase
408 Eur. J. Med. Chem. 2008; 43: 862-871.
- 409 4. Doehner W. Anker SD. Xanthine oxidase inhibition for chronic heart failure: is
410 allopurinol the next therapeutic advance in heart failure. Heart. 2005; 91: 707-709.
- 411 5. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular
412 mechanisms and pathophysiological implications. J Physiol. 2004; 555: 589-606.
- 413 6. Lee C, Liu Xk, Zweier JL. Regulation of xanthine oxidase by nitric oxide and
414 Peroxynitrite. J Biol Chem. 2000; 275: 9369-9376.

- 415 7. Fernandes AS, Gaspar J, Cabral MF, Caneiras C, Guedes R, Rueff J, Castro M.
416 Macrocyclic copper (II) Complexes: superoxide scavenging activity, Structural studies
417 and cytotoxicity evaluation. J Inorg Biochem. 2007; 101: 849-858.
- 418 8. Mahnaz Hadizadeh, Ezzatollah Keyhani, Jacqueline Keyhani, Cyrus Khodadadi.
419 Functional and structural alterations induced by copper in xanthine oxidase. Acta Biochim
420 Biophys Sin. 2009; 603-617.
- 421 9. Sau AK, Mondal MS, Mitra S. Interaction of Cu²⁺ ion with milk xanthine oxidase.
422 Biochim Biophys Acta., 2001; 1544: 89-95.
- 423 10. Dave S, Bansal N. International Journal of Basic and Applied Chemical Sciences
424 ISSN: 2277-2073
- 425 11. Riley DP. Functional mimics of superoxide dismutase enzymes as therapeutic agents,
426 Chem. Rev. 1999; 99: 2573-2587.
- 427 12. Bienvenue E, Choua S, Lobo-Recio MA, Marzin C, Pacheco P, Seta P, Tarrago G.
428 Structure and superoxide dismutase activity of Ru(II), Cu(II), and Mn(II) macrocyclic
429 complexes. J. Inorg. Biochem., 1995; 57: 157-168.
- 430 13. Ana S. Fernandes, Jorge Gaspar, Fatima Cabral M, Catia Caneiras, Rita Guedes, Jose
431 Rueff, Matilde Castro, Judite Costa, Nuno G. Macrocyclic copper(II) complexes:
432 Superoxide scavenging activity, structural studies and cytotoxicity evaluation Oliveira
433 Journal of Inorganic Biochemistry. 2007; 101: 849-858.
- 434 14. Autzen S, Korth H, Boese R, Groot HG, Sustmann R. Stabilizing Reactive metal-ligand
435 Fragmentation. Eur. J. Inorg. Chem. 2003; 1401-1410.
- 436 15. Durackova Z, Labuda J. Superoxidase dismutase mimetic activity of macrocyclic Cu(II)-
437 Tetraanhydroaminobenzaldehyde (TAAB) complex. J. Inorg. Biochem. 1995; 58: 297-

- 438 303.
- 439 16. Kimura E, Sakonaka A, Nakamoto M. Interplay between Metal ions and Nucleic acids.
440 Biochim. Biophys. Acta. 1981; 678: 172-179.
- 441 17. Kimura E, Yatsunami A, Watanabe A, Machida R, Koike T, Fujioka H, Kuramoto Y,
442 Sumomogi M, Kunimitsu K, Yamashita A. Further studies on superoxide dismutase
443 activities of macrocyclic polyamine complexes of copper(II). Biochim. Biophys. Acta.
444 1983; 745: 37-43.
- 445 18. Sartaj Tabassum, Ahamad Asim, Farukh Arjmand, Mohd. Afzal, Vivek Bagchi. Synthesis
446 and characterization of copper(II) and zinc(II)-based potential chemotherapeutic
447 compounds: Their biological evaluation viz. DNA binding profile, cleavage and
448 antimicrobial activity. Eur. J. Med. Chem. 2012; 58: 308-316.
- 449 19. Gloe K Ed. Macrocyclic Chemistry. Current Trends and Future Perspectives. Springer,
450 Berlin. 2005.
- 451 20. Singh DP, Kumar R, Malik V, Tyagi P. Synthesis and characterization of complexes of
452 Co(II), Ni(II), Cu(II), Zn(II), and Cd(II) with macrocycle 3,4,11,12-tetraoxo-
453 1,2,5,6,9,10,13,14-octaaza-cyclohexadeca-6,8,14,16-tetraene and their biological screening.
454 Transition Met. Chem. 2007; 32:1051-1055
- 455 21. Singh DP, Kumar R, Malik V, Tyagi P. Template synthesis, spectroscopic studies and
456 biological activities of macrocyclic complexes derived from thiocarbohydrazide and
457 glyoxal. J. Enzym. Inhib. Med. Chem. 2007; 22: 177-82.
- 458 22. Kadam RS, Iyer KR. Isolation of different animal liver xanthine oxidase containing
459 fractions and determination of kinetic parameters for xanthine. Indian J. Pharm. Sci.

- 2007; 69: 41-45.
23. Litwack G, Bothwell JW, Williams JN, Elvehjem RJ. A colorimetric assay for xanthine oxidase in rat liver homogenates. *J. Biol. Chem.* 1952; 200: 303-310.
24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. *J. Biol. Chem.* 1951; 193: 265-275.
25. Yamaguchi T, Takamura H, Matoba T, Terao J. HPLC method for evaluation of the free radical-scavenging activity of foods by using 1, 1-diphenyl-2 picrylhydrazyl. *Bioscience Biotechnology and Biochemistry.* 1998; 62:1201-1204.
26. Kulkarni AP, Aradhya M, Divakar S. Isolation and identification of a radical scavenging Antioxidant- punicalagin from pith and carpellary membrane of pomegranate fruit. *Food Chemistry.* 2004; 87: 551- 557.
27. Yen GC, Chen HY. Antioxidant activity of various tea extracts in relation to their antimutagenicity. *Journal of Agricultural and Food Chemistry.* 1995; 43: 27-32.
28. Decker EA, Welch B. Role of ferritin as a lipid oxidation catalyst in muscle food. *Journal of Agricultural And Food Chemistry.* 1990; 38: 674-677.
29. Schüttelkopf AW, Aalten, D.M.F.V. PRODRG—a tool for high-throughput crystallography of protein–ligand complexes, *Acta Crystallogr., D60.* 2004, 1355–1363.
30. Thomsen R, Christensen MH. MolDock: a new technique for high-accuracy molecular docking, *J. Med. Chem.* 2006; 49: 3315-3321.
31. Gupta S, Rodrigues LM, Esteves AP. Oliveira-Campos AMF. Synthesis of N-aryl-5-amino-4-cyanopyrazole derivatives as potent xanthine oxidase inhibitors. *Eur. J. Med. Chem.* 2008; 43: 771- 780.
32. Chen CW, Ho CT. Antioxidant properties of polyphenols extracted from green and

- 483 black teas. Journal of Food Lipids. 2007; 2: 35-46.
- 484 33. Jadhav SJ, Nimbalkar SS. Kulkarni AD, & Madhavi D L. (1996). Lipid oxidation in
- 485 biological and food systems. In D. L. Madhavi, S. S. Deshpande, & D. K. Salunke (Eds.),
- 486 Food antioxidants (pp. 5–63). New York: Marcel Dekker.
- 487 34. Duh PD, Tu YY, Yen GC. Antioxidant activity of water extract of Harng Jyur
- 488 (Chrysanthemum morifolium Ramat). Lebensmittel Wissenschaft und Technologie.
- 489 1999; 32: 269-277.
- 490 35. Gordon MH. The mechanism of antioxidant action in vitro. London: Elsevier Applied
- 491 Science. 1990; 1-18.

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509